Wuxi Biologics, of Shanghai, said partner Tychan Pte Ltd., of Singapore, dosed the first patient with Zika antibody tyzivumab in a phase Ia trial in Singapore. Tyzivumab is directed against a specific quaternary epitope of the envelope (E) protein on the surface of the virus, limiting viral fusion to host cells and preventing viral replication.